Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Laurent Levy

Nanobiotix S.A.

Biotech 365 provides business support services for biotech companies, focusing on fundraising, licensing, and connecting companies with healthcare investors through their global network.

Biotech 365

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Neovacs S.A.

Poxel SA is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, focusing on non-alcoholic steatohepatitis (NASH) and rare disorders.

Poxel SA

Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is one rooted in designing pioneer physical based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges.   

Nanobiotix’s novel first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Furthermore, Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies. 

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The Company’s headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany. More: www.nanobiotix.com

Bpifrance

European Investment Bank

Johnson & Johnson Innovation – JJDC

Amorçage Rhône Alpes

Apicap

Karista

Matignon Technologies

Seventure Partners

Crédit Mutuel Innovation

Nanobiotix

LianBio, partenaire de Nanobiotix, transfère ses droits de développement et de commercialisation de NBTXR3 en Chine et sur d'autres marchés asiatiques. PR : https://lnkd.in/e6ATUM7T

Nanobiotix partner LianBio assigns its development and commercialization rights for NBTXR3 in China and other Asian Markets. PR link: https://lnkd.in/eE6vkSkq

Avec toute notre gratitude pour votre soutien afin de révolutionner le traitement de millions de patients à travers le monde, nous vous souhaitons de joyeuses fêtes à tous !

With gratitude for your support in revolutionizing treatment for millions of patients, we offer happy holidays to all!

Happy Thanksgiving to all of our friends, colleagues, supporters and patients in the United States. We are inspired by the spirit of Thanksgiving as we reflect on the important progress our incredible team has achieved this year toward achieving our mission of revolutionizing treatment for millions. Best wishes and enjoy the holiday!

Metric
Company Name	Nanobiotix S.A.	Biotech 365	Neovacs S.A.	Poxel SA
Symbol	NANO		ALNEV
MSH ID	COM:NANOBIOTIX	COM:BIOTECH-365	COM:NEOVACS	COM:POXEL
Market	STOCKS	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare	Financial Services & Finance	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology Business Services	Biotechnology	Biotechnology
Country	FR	FR	FR	FR
Stage			Post-IPO Debt	Post-IPO Debt
Employee Count	102		22
Website	nanobiotix.com	biotech-365.com	neovacs.com	poxel.com
LinkedIn	nanobiotix		neovacs	poxel
Founders

Metric
Market Cap	251.32M		52.99K
Enterprise Value
Monthly Web Traffic		68		4.88K
Web Traffic Growth		-0.57		-0.63
Valuation
Raised Capital			4.77M	50M

Metric
Revenue	31.75M	563.41K
Revenue (LTM)
Revenue (NTM)
Gross Profit	38.24M	-7.13M
EBITDA	-30.49M	-7.12M
Operating Income	-32.10M	-7.30M
Net Income	-41.93M	-9.24M
EPS	-1.14	-0.00
Diluted EPS	-1.14	-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	1.07	-9.71
Operating Profit Margin	-0.59	-12.95
EBITDA Margin	-0.96	-12.64
Net Profit Margin	-0.79	-16.39
Return on Equity	2.83	-0.12
Return on Assets	-0.39	-0.11
Return on Capital Employed	5.25	-0.14

COM:NANOBIOTIX

Nanobiotix

Last Close

3.50

25/11 09:24

Market Cap

237.91M

Beta: -

Volume Today

19.84K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-4.31
P/B Ratio	-9.09
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	43.44	5.78
EV Multiple	-4.61	-0.04

Metric
Days Sales Outstanding
Days Payables Outstanding		1.22K
Days Inventory Outstanding	0.00
Operating Cycle	59.03	11.67K
Cash Conversion Cycle	1.21K	11.39K
Asset Turnover	0.49	0.01

Metric
Operating Cash Flow	-20.55M	-2.02M
Free Cash Flow	-20.90M	-2.24M
Cash Flow to Debt	-0.02	-1.47
Operating Cash Flow/Sales	-0.02	-3.59
Free Cash Flow Yield	-0.11	-0.00

Metric
Cash & Equivalents	79.52M	936.97K
Accounts Receivable	-1.15M
Inventory	211.25K
Goodwill
Debt to Capitalization	1.96	0.06
Debt to Assets	0.89	0.02
Current Ratio	1.38	2.32
Quick Ratio	1.75	1.34

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue